PCIA
EDIT icon

Prime Capital Investment Advisors’s Editas Medicine EDIT Stock Holding History

Prime Capital Investment Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67K Sell
27,111
-1,430
-5% -$3.03K ﹤0.01% 1014
2025
Q4 		$58.5K Sell
28,541
-678
-2% -$1.96K ﹤0.01% 1000
2025
Q3 		$101K Sell
29,219
-3,039
-9% -$8.48K ﹤0.01% 969
2025
Q2 		$71K Sell
32,258
-15,588
-33% -$25.5K ﹤0.01% 926
2025
Q1 		$55.5K Sell
47,846
-1,679
-3% -$2.47K ﹤0.01% 1024
2024
Q4 		$62.9K Buy
+49,525
New +$126K ﹤0.01% 910

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prime Capital Investment Advisors's EDIT Position: Q1 2026 in Review

Prime Capital Investment Advisors reduced its Editas Medicine (EDIT) stake by 5% in Q1 2026, selling an estimated $3.03K and leaving 27,111 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

Prime Capital Investment Advisors first reported a position in EDIT in Q4 2024 and has held it in 6 quarters since. The position peaked at $101K in Q3 2025. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Prime Capital Investment Advisors held 27,111 shares of Editas Medicine worth $67K as of Q1 2026.
  • Prime Capital Investment Advisors sold 1,430 Editas Medicine shares in Q1 2026, an estimated $3.03K.
  • Editas Medicine made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #1014 holding.
  • Prime Capital Investment Advisors first reported a position in Editas Medicine in Q4 2024 and has held it in 6 quarters since.
  • Prime Capital Investment Advisors's Editas Medicine position peaked at $101K in Q3 2025.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.